Actithera draws new investors to radiopharma drug pitch
BioPharma Drive: Drug Pricing
JULY 9, 2025
Published July 9, 2025 Gwendolyn Wu Senior reporter post share post print email license Actinium is one of several radioisotopes favored by biotechnology companies developing drugs for cancer. billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive. Private radiopharma companies, meanwhile, drew more than $1.1
Let's personalize your content